More about Dr. Lal PathLabs Limited
Fundamentals for Dr. Lal PathLabs Limited
Regulatory Filings for Dr. Lal PathLabs Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Dr. Lal PathLabs Limited
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
Revenue projections:
Dr. Lal PathLabs Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 39.57900 |
| debtToEquity | 6.44100 |
| earningsGrowth | -0.06600 |
| revenueGrowth | 0.10600 |
| grossMargins | 0.58503 |
| operatingMargins | 0.20794 |
| trailingEps | 31.69000 |
| forwardEps | 35.43041 |
Dr. Lal PathLabs Limited's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
LALPATHLAB's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
With a forward EPS greater than its trailing EPS, LALPATHLAB is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.
Price projections:
Over time, LALPATHLAB's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.
Insider Transactions:
38 transactions were made to sell LALPATHLAB shares, with market price of 2992.748679713199.1 purchases of Dr. Lal PathLabs Limited stock were recorded, with market price of 3308.5 per share.The list of insider transactions is inconclusive, with no evident trend emerging to suggest a notable shift in company behavior or outlook.
Recommendation changes over time:
Analysts' buy bias for Dr. Lal PathLabs Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Dr. Lal PathLabs Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape